Results 41 to 50 of about 10,682 (172)

Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke

Pharmaceuticals, 2010
Cannabis contains the psychoactive component delta9-tetrahydrocannabinol (delta9-THC), and the non-psychoactive components cannabidiol (CBD), cannabinol, and cannabigerol.
Michihiro Fujiwara, Kazuhide Hayakawa, Kenichi Mishima   +2 more
doaj   +1 more source

Expression of cannabinoid 1 and, 2 receptors and the effects of cannabinoid 1 and, 2 receptor agonists on detrusor overactivity associated with bladder outlet obstruction in rats

BMC Urology, 2017
Background This study investigated changes in the expression of cannabinoid (CB) receptors and the effects of CB1 and CB2 agonists on detrusor overactivity (DO) associated with bladder outlet obstruction (BOO) in rats.
Sung Dae Kim, Kang Jun Cho, Joon Chul Kim   +2 more
doaj   +1 more source

Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212–2 in renal cell carcinoma

BMC Cancer, 2018
Background The anti-tumor properties of cannabinoids have been investigated in many in vitro and in vivo studies. Many of these anti-tumor effects are mediated via cannabinoid receptor types 1 and 2 (CB1 and CB2), comprising the endocannabinoid system ...
Mohammed I. Khan, Anna A. Sobocińska, Klaudia K. Brodaczewska, Katarzyna Zielniok, Malgorzata Gajewska, Claudine Kieda, Anna M. Czarnecka, Cezary Szczylik   +7 more
doaj   +1 more source

Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.

PLoS ONE, 2020
BACKGROUND/OBJECTIVE:Patients with non-small cell lung cancer (NSCLC) develop resistance to antitumor agents by mechanisms that involve the epithelial-to-mesenchymal transition (EMT).
Lara Milian, Manuel Mata, Javier Alcacer, María Oliver, María Sancho-Tello, José Javier Martín de Llano, Carlos Camps, José Galbis, Julian Carretero, Carmen Carda   +9 more
doaj   +1 more source

Antagonism of CB1‐mediated discriminative‐stimulus effects by CB1 neutral and inverse‐agonist antagonists

The FASEB Journal, 2012
CB1 inverse‐agonist antagonists (e.g., rimonabant) have behavioral effects that limit their clinical utility. Recent data suggest that CB1 neutral antagonists may not have rimonabant‐like effects, raising the possibility of improved clinical utility. The present studies were conducted to compare how inverse‐agonist antagonists (SR141716A, AM 6538) and ...
Brian D. Kangas, Kiran Vemuri, Ganesh Thakur, Alex Makriyannis, Jack Bergman   +4 more
openaire   +1 more source

Targeting cannabinoid CB2 receptors in the Central Nervous System. Medicinal chemistry approaches with focus on neurodegenerative disorders

Frontiers in Neuroscience, 2016
Endocannabinoids activate two types of specific receptors, namely cannabinoid CB1 and CB2. Contrary to the psychotropic actions of agonists of CB1 receptors, and serious side effects of the selective antagonists of this receptor, drugs acting on CB2 ...
Gema Navarro, Paula Morales, Carmen Rodríguez-Cueto, Javier Fernández-Ruiz, Nadine Jagerovic, Rafael Franco   +5 more
doaj   +1 more source

Agonists of CB1 and NMDA receptors decrease the toxic effect of organophosphorus compound paraoxon on PC12 cells [PDF]

The Ukrainian Biochemical Journal, 2019
Pharmacological studies allow to suggest that activation of cannabinoid type 1 receptors (CB1) have a neuroprotective role against toxicity induced by organophosphate agents, but the exact mechanisms of this effect as well as interaction with receptors ...
F. Salem, F. Bahrami, Z. Bahari, Z. Jangravi, S. Najafizadeh-Sari   +4 more
doaj   +1 more source

The Interplay between the Immune and the Endocannabinoid Systems in Cancer

Cells, 2021
The therapeutic potential of Cannabis sativa has been recognized since ancient times. Phytocannabinoids, endocannabinoids and synthetic cannabinoids activate two major G protein-coupled receptors, subtype 1 and 2 (CB1 and CB2).
Mariantonia Braile, Simone Marcella, Gianni Marone, Maria Rosaria Galdiero, Gilda Varricchi, Stefania Loffredo   +5 more
doaj   +1 more source

Quinazoline-2,4(1H,3H)-dione derivatives as new class of CB1 Agonists: A pharmacophore-based virtual screening workflow and Lead discovery [version 1; peer review: 2 approved]

F1000Research
Background The cannabinoid 1 (CB1) receptor is the primary target of Δ9-tetrahydrocannabinol (Δ9-THC), the psychoactive component of cannabis sativa (commonly known as “kif” in Morocco).
Fouad Khalil, Abdellah EL AISSOUQ, MOURAD STITOU, Mohamed Enneiymy, Said El Rhabori, Hicham Zaitan, Abdelkrim Ouammou   +6 more
doaj   +1 more source

The Selective CB2 Agonist COR167 Reduced Symptoms in a Mice Model of Trauma-Induced Peripheral Neuropathy through HDAC-1 Inhibition

Biomedicines, 2023
Neuropathic pain is a chronic disabling condition with a 7–10% of prevalence in the general population that is largely undertreated. Available analgesic therapies are poorly effective and are often accompanied by numerous side effects.
Vittoria Borgonetti, Claudia Mugnaini, Federico Corelli, Nicoletta Galeotti   +3 more
doaj   +1 more source